SCHEMBL25183530

SCHEMBL25183530

[CH2][C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O

nearest known ligand 0.58

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ TMPRSS2 O15393 1/20 0.45
▸ POLRMT O00411 1/20 0.33
▸ MAP4K4 O95819 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gs-441524 SCHEMBL10120689 0.84 TMPRSS2 (0.60) TMPRSS2POLRMT
Gs-441524 SCHEMBL22663744 0.84 TMPRSS2 (0.60) TMPRSS2POLRMT
Gs-441524 SCHEMBL22096285 0.84 TMPRSS2 (0.60) TMPRSS2POLRMT
Gs-441524 SCHEMBL24975226 0.84 TMPRSS2 (0.60) TMPRSS2POLRMT
Gs-441524 SCHEMBL10120691 0.84 TMPRSS2 (0.60) TMPRSS2POLRMT
Gs-441524 SCHEMBL15998246 0.84 TMPRSS2 (0.60) TMPRSS2POLRMT
Gs-441524 SCHEMBL24667691 0.84 TMPRSS2 (0.60) TMPRSS2POLRMT
Gs-441524 SCHEMBL23870459 0.84 TMPRSS2 (0.60) TMPRSS2POLRMT
Gs-441524 SCHEMBL22142944 0.84 TMPRSS2 (0.60) TMPRSS2POLRMT
Gs-441524 SCHEMBL31174011 0.84 TMPRSS2 (0.60) TMPRSS2POLRMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4204421-B1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES INC (US) 2024-05-15 — — EP disclosed
US-20240150359-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2024-05-09 — — US disclosed
EP-4320128-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2024-02-14 — — EP disclosed
US-11851438-B2 1′-cyano nucleoside analogs and methods for treatment of viral infections GILEAD SCIENCES, INC. (US) 2023-12-26 — — US disclosed
US-11845755-B2 Compounds and methods for treatment of viral infections GILEAD SCIENCES, INC. (US) 2023-12-19 — — US disclosed
US-20230295172-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
US-20230279015-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2023-09-07 — — US disclosed
US-20230279013-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2023-09-07 — — US disclosed
WO-2023167944-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2023-09-07 — — WO disclosed
US-20230279014-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2023-09-07 — — US disclosed
EP-4200301-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-06-28 — — EP disclosed
US-20230151043-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150359-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS HAVCR2, EIF2AK2, OAT TMPRSS2 112/4885POLRMT 16/4885MAP4K4 4104/4885
US-20230279015-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS HAVCR2, EIF2AK2, OAT TMPRSS2 112/4885POLRMT 16/4885MAP4K4 4104/4885
US-20230279014-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS HAVCR2, EIF2AK2, OAT TMPRSS2 112/4885POLRMT 16/4885MAP4K4 4104/4885
US-11851438-B2 1′-cyano nucleoside analogs and methods for treatment of viral infections TYMP, PNP, SAMHD1 TMPRSS2 2073/4885POLRMT 16/4885MAP4K4 4079/4885
US-20230151043-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS HAVCR2, EIF2AK2, ACE TMPRSS2 141/4885POLRMT 20/4885MAP4K4 3833/4885
US-20230279013-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS HAVCR2, EIF2AK2, OAT TMPRSS2 112/4885POLRMT 16/4885MAP4K4 4104/4885
US-11845755-B2 Compounds and methods for treatment of viral infections HAVCR2, EIF2AK2, OAT TMPRSS2 112/4885POLRMT 16/4885MAP4K4 4104/4885
US-20230295172-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS HAVCR2, EIF2AK2, OAT TMPRSS2 112/4885POLRMT 16/4885MAP4K4 4104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback